Dogwood Therapeutics, Inc. (DWTX) Deferred Foreign Income Tax Expense (Benefit)

Dogwood Therapeutics, Inc. Deferred Foreign Income Tax Expense (Benefit)

Dogwood Therapeutics, Inc. (DWTX) reported Deferred Foreign Income Tax Expense (Benefit) of -$2.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Income Tax

us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-08-14

• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for the quarter ending 2026-06-30 was -$2.48M, a 1664995.30% decline year-over-year.
• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for the quarter ending 2026-03-31 was $1.19K, a 99.37% decline year-over-year.
• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for the quarter ending 2025-12-31 was $31.84K.
• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for the quarter ending 2025-09-30 was -$1.44K.
• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for fiscal 2025 was $221.10K.
• Dogwood Therapeutics, Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was -$503.00.